• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

    21.14 -2.69 (-11.29%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,593,781
    Open 23.92
    Bid (Size) 21.10 (400)
    Ask (Size) 21.26 (100)
    Prev. Close 23.83
    Today's Range 20.21 - 24.05
    52wk Range 10.41 - 127.91
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗
    Via Stocktwits
    News headline image
    Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
    From Sarepta Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -0.8%
    -0.8%
    1 Month
    -1.9%
    -1.9%
    3 Month
    -3.7%
    -3.7%
    6 Month
    +9.9%
    +9.9%
    1 Year
    -82.1%
    -82.1%

    More News

    Read More
    News headline image
    Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Why Is SRPT Stock Falling Today? ↗
    Via Stocktwits
    News headline image
    Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears
    Via MarketMinute
    News headline image
    Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
    Via MarketMinute
    News headline image
    How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗
    Via Investor's Business Daily
    News headline image
    Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys ↗
    Via Stocktwits
    News headline image
    Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tech Edges Up Ahead Of Nvidia's Earnings, Bitcoin Sinks Below $90,000: What's Moving Markets Wednesday? ↗
    Via Benzinga
    News headline image
    Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy ↗
    Via Stocktwits
    Topics Death
    News headline image
    2 Beaten-Down Stocks to Avoid Right Now ↗
    Via The Motley Fool
    Topics Death
    News headline image
    Sarepta Shares Jump After FDA Approves Updated Elevidys Label ↗
    Via Benzinga
    News headline image
    Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    Via Benzinga
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    Via Benzinga
    News headline image
    Analyst Ratings Send Ripples Through Markets: Sarepta's Resilience vs. Pinterest's Plunge
    Via MarketMinute
    News headline image
    This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
    Via Benzinga
    News headline image
    Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
    Via MarketMinute
    Topics Death
    News headline image
    Which stocks are experiencing notable movement on Tuesday? ↗
    Via Chartmill
    News headline image
    Gold Falls Over 1%; Uber Shares Decline After Q3 Results ↗
    Via Benzinga

    Frequently Asked Questions

    Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
    Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
    The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
    What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
    The current price of Sarepta Therapeutics, Inc. - Common Stock is 21.14
    When was Sarepta Therapeutics, Inc. - Common Stock last traded?
    The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 01/12/26 04:00 PM ET
    What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
    The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.97B
    How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
    Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.